• RxStrategies Clinical Insights — November 2015, Issue 2

    Welcome to the second November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.     New Drug Approval Ninlaro® (ixazomib) November 20, 2015 – The U.S. Food and Drug Administration approved ixazomib (Ninlaro®, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical… Read more »

  • RxStrategies Clinical Insights — November Issue 1

    Welcome to the first November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Imlygic™ (talimogene laherparepvec) October 27, 2015 — The U.S. Food and Drug Administration approved Imlygic™ (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the… Read more »

  • RxStrategies, Inc. Names Skip Devanny Chief Revenue Officer

    BOCA RATON, Fla., October 28, 2015—RxStrategies, Inc. (www.rxstrategies.com) is pleased to announce the appointment of Skip Devanny to the position of Chief Revenue Officer. In this new role, Skip joins the RxStrategies’ senior leadership team and has responsibility for sales and marketing including the delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace. “I… Read more »

  • RxStrategies Connects with Industry Leaders from Coast to Coast

    It has been a pleasure for the RxStrategies team to connect with industry leaders during events across the country this month. Last week, we traveled to Jekyll Island, Georgia, for the Georgia Association for Primary Health Care (GAPHC) 2015 Annual Conference, and to Sacramento, California, for the California Primary Care Association (CPCA) Annual Conference. To learn more about… Read more »

    Last week, we traveled to Jekyll Island, Georgia, for the Georgia Association for Primary Health Care (GAPHC) 2015 Annual Conference, and to Sacramento, California, for the California Primary Care Association (CPCA) Annual Conference.

    To learn more about our 340B solutions, and how to position your organization for success with the 340B Drug Pricing Program, call us at 877-GoGetRx.

     

    -->
  • RxStrategies Clinical Insights — October Issue 1

    Welcome to the first October edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Tresiba® (insulin degludec injection) September 25, 2015 — The U.S. Food and Drug Administration approved Tresiba® (insulin degludec injection) and Ryzodeg® 70/30 (insulin degludec/insulin… Read more »

  • RxStrategies Clinical Insights — September 2015 Issue 1

    Welcome to the first September edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Xuriden™ (uridine triacetate) September 4, 2015 — The U.S. Food and Drug Administration approved Xuriden™ (uridine triacetate), the first FDA-approved treatment for patients with… Read more »

  • September 340B Insider

    Welcome to the September edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   RxStrategies’ Perspective: Proposed Mega Reg Guidance As you know, the Health Resources and Services Administration (HRSA) released on August 28, the provisions of the 340B Drug Pricing Program Omnibus Guidance (Proposed Guidance). The Proposed Guidance… Read more »